Mostrar el registro sencillo del ítem
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients.
dc.contributor.author | Martínez, Nerea | |
dc.contributor.author | Sánchez-Beato, Margarita | |
dc.contributor.author | Carnero, Amancio | |
dc.contributor.author | Moneo, Victoria | |
dc.contributor.author | Tercero, Juan C. | |
dc.contributor.author | Fernández, Isabel | |
dc.contributor.author | Navarrete, Mercedes | |
dc.contributor.author | Jimeno, José | |
dc.contributor.author | Piris, Miguel A. | |
dc.date.accessioned | 2024-01-11T10:13:11Z | |
dc.date.available | 2024-01-11T10:13:11Z | |
dc.date.issued | 2005 | |
dc.identifier.issn | 1535-7163 | spa |
dc.identifier.uri | https://hdl.handle.net/10641/3685 | |
dc.description.abstract | Ecteinascidin 743 (ET-743; Yondelis, Trabectedin) is a marine anticancer agent that induces long-lasting objective remissions and tumor control in a subset of patients with pretreated/resistant soft-tissue sarcoma. Drug-induced tumor control is achievable in 22% of such patients, but there is no clear indication of the molecular features correlated with clinical sensitivity/resistance to ET-743. Nine low-passage, soft-tissue sarcoma cell lines, explanted from chemo-naive patients with different patterns of sensitivity, have been profiled with a cDNA microarray containing 6,700 cancer-related genes. The molecular signature of these cell lines was analyzed at baseline and at four different times after ET-743 exposure. The association of levels of TP53 mutation and TP73 expression with ET-743 sensitivity and cell cycle kinetics after treatment was also analyzed. Gene expression profile analysis revealed up-regulation of 86 genes and down-regulation of 244 genes in response to ET-743. The ET-743 gene expression signature identified a group of genes related with cell cycle control, stress, and DNA-damage response (JUNB, ATF3, CS-1, SAT, GADD45B, and ID2) that were up-regulated in all the cell lines studied. The transcriptional signature 72 hours after ET-743 administration, associated with ET-743 sensitivity, showed a more efficient induction of genes involved in DNA-damage response and apoptosis, such as RAD17, BRCA1, PAR4, CDKN1A, and P53DINP1, in the sensitive cell line group. The transcriptional signature described here may lead to the identification of ET-743 downstream mediators and transcription regulators and the proposal of strategies by which ET-743-sensitive tumors may be identified. | spa |
dc.language.iso | eng | spa |
dc.publisher | Molecular Cancer Therapeutics | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.title | Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | SMUR | spa |
dc.rights.accessRights | metadata only access | spa |
dc.description.extent | 1,83 MB | spa |
dc.identifier.doi | 10.1158/1535-7163.MCT-04-0316 | spa |
dc.relation.publisherversion | https://aacrjournals.org/mct/article/4/5/814/234655/Transcriptional-signature-of-Ecteinascidin-743 | spa |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
CIENCIAS EXPERIMENTALES [324]